Sight Sciences (SGHT) Q4 2025 earnings review
A Remarkable Turnaround in Cash Burn and the Dawn of Reimbursed Dry Eye
Sight Sciences successfully closed out a turbulent 2025 by returning to top-line growth and nearly eliminating its cash burn. Fourth-quarter revenue climbed 7% YoY to $20.4M, beating previous sluggish trends caused by strict Medicare coverage limits on glaucoma devices. The biggest story, however, is the cash flow and operational discipline: Q4 cash usage plummeted to just $0.4M, compared to $11.6M at the start of the year, driven by a 23% reduction in adjusted operating expenses. Meanwhile, the strategic gamble to transition the TearCare (Dry Eye) business from a cash-pay model to a reimbursed procedure is showing early signs of paying off, with segment revenue jumping sequentially. Management's 2026 guidance projects 6-14% total growth, heavily relying on scaling the newly reimbursed Dry Eye segment.
🐂 Bull Case
By reducing quarterly cash usage to a mere $0.4 million while maintaining a $92M cash balance, management has effectively removed the overhang of future equity dilution. The 13% full-year reduction in operating expenses proves their commitment to profitable growth.
The establishment of Medicare fee schedules for TearCare by two major contractors in late 2025 is a massive inflection point. With 2026 Dry Eye revenue guided to $5-7M (up from $1.6M in 2025), a lucrative new revenue stream is activating.
🐻 Bear Case
Despite surviving the 'one MIGS' Medicare restrictions, the core Surgical Glaucoma segment is guided to grow just 2-7% in 2026. This implies a mature, highly competitive market rather than a rapid expansion phase.
The company remains exposed to China tariffs, which continue to slightly offset gross margin gains in the glaucoma segment. Moving manufacturing out of China carries execution risks.
⚖️ Verdict: 🟢
Bullish. Management executed masterfully on the things they could control: slashing operating expenses, protecting gross margins (~86%), and securing milestone Medicare reimbursements for TearCare. The foundational pieces are set for high-margin, cash-generative growth in 2026.
Key Themes
TearCare Reimbursement Ignites Dry Eye Segment
Reversing. After intentionally starving the Dry Eye segment for three quarters to pivot away from a cash-pay model, the strategy is working. The establishment of Medicare fee schedules (covering ~10.4M lives) immediately sparked a Q4 revenue jump to $0.7M, more than triple the Q3 run-rate. With Q4 Dry Eye gross margin surging to 68% (from 51% YoY) due to higher average selling prices, the segment is primed to become a high-margin growth engine.
Surgical Glaucoma Market Share Consolidation
Accelerating. The surgical glaucoma segment has successfully navigated the disruptive Medicare Local Coverage Determinations (LCDs) that restricted combo-MIGS procedures. By positioning OMNI as the comprehensive 'one MIGS' solution, the segment returned to 5% YoY growth in Q4, driven by higher average selling prices and increased ordering accounts. Management continues to leverage this momentum into the pseudophakic standalone market.
Operational Discipline Drives Down Burn Rate
Accelerating. The financial turnaround on the bottom line is stark. Q4 adjusted operating expenses fell 23% YoY to $18.9M. By aggressively restructuring earlier in the year (cutting G&A without hurting the commercial team), they reduced Q4 net loss to $4.2M ($0.08/share) versus $11.8M a year ago. The pathway to cashflow breakeven appears imminent.
Macro: Tariffs Restricting Margin Expansion
Stable. The medical device industry remains heavily impacted by U.S. tariffs on Chinese manufacturing. Sight Sciences noted that Surgical Glaucoma gross margins in Q4 (88%) were slightly offset by these tariff costs. While they have plans to shift manufacturing out of China, this macroeconomic headwind will persist through early 2026.
Product Innovation: OMNI Edge with TruSync
The rollout of the next-generation OMNI Edge surgical system featuring TruSync technology continues to drive surgeon adoption. This technology allows for proprietary motion-synchronized viscoelastic delivery, affording physicians more customized viscodilation. It is a critical differentiator aiding the company's market share capture against newer entrants.
Modest Glaucoma Growth Expectations Contradict Market Dominance Narrative
While management touts taking significant market share in the new single-MIGS environment, the data points to a maturing market. FY26 Surgical Glaucoma guidance calls for only 2% to 7% YoY growth. If OMNI is vastly superior and actively displacing competitors, the top-line growth in its core segment should ideally be breaking into double digits, suggesting broader market procedure volumes might be stagnating.
Other KPIs
Stable. Gross margins remained incredibly robust, matching the 87% print from Q4 2024. Despite tariff pressures on the glaucoma side, the sudden increase in the Dry Eye segment's margin (from 51% to 68%) due to higher reimbursement pricing helped anchor the consolidated figure.
Accelerating improvement. A 13% reduction compared to $101.3M in FY24. This massive expense cut—largely driven by lower personnel, legal, and stock-based compensation—is the primary reason the company avoided raising dilutive capital this year.
Guidance
Accelerating. The midpoint of $85M implies a 10% YoY growth rate, a stark reversal from the 3% contraction experienced in FY25. This assumes a stable core Glaucoma business layered with explosive growth in the Dry Eye segment.
Accelerating slightly. Represents growth of 2% to 7% compared to flat (0%) growth in 2025. This reflects a normalized baseline after the 2024/2025 Medicare LCD disruptions and relies on continued execution in the standalone market.
Accelerating massively. Compared to $1.6M in 2025, this represents a ~275% YoY surge at the midpoint. This is the ultimate proof-of-concept metric for the company's shift into the reimbursed dry eye market.
Reversing. After cutting expenses heavily in 2025 to $87.8M, management is guiding for a 6% to 9% increase. They noted this is for targeted commercial investments to scale the newly reimbursed Dry Eye market and the standalone glaucoma opportunity.
Key Questions
TearCare Payer Expansion Timeline
You successfully secured fee schedules from Novitas and First Coast, covering ~30% of Medicare fee-for-service lives. What is the realistic timeline for securing the remaining Medicare Administrative Contractors (MACs) and major commercial payers?
Manufacturing Diversification Progress
Earlier in the year, you outlined a 9-to-12-month timeline to establish third-party manufacturing lines outside of China to mitigate the 145% tariff hit. Are those new lines still on track for Q1 2026, and how much margin relief should we model once completed?
Standalone Pseudophakic Market Contribution
You've heavily emphasized targeting the pseudophakic standalone market for OMNI procedures. What percentage of your Surgical Glaucoma mix currently comes from standalone cases versus combination cataract procedures, and how fast is it growing?
Alcon Litigation Impact
Are there any updates regarding the Alcon patent litigation overhang and potential final orders from the judge, specifically regarding past damages or ongoing royalties?